Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00986713

Enrollment

400

Registered

2009-09-30

Start date

2008-06-30

Completion date

2010-10-31

Last updated

2009-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive Pulmonary Aspergillosis

Brief summary

The purpose of this study is to determine whether inhalation with aerosolized amphoterin B 10mg/d is more effective than aerosolized amphoterin B 2mg/d to reduce the incidence of invasive pulmonary aspergillosis.

Interventions

DRUGAmphotericin B

Aerosolized Amphotericin B,2mg/day or 10mg/day

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* 65ys≥age≥18ys * renal transplant recipients

Exclusion criteria

* subjects with hypersensitivity to amphotericin B * receipt of inhalational or intravenous amphotericin B within last 30 days * subjects with known invasive fungal infection before renal transplant * subjects with pneumonia

Design outcomes

Primary

Measure	Time frame
invasive pulmonary aspergillosis	3 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026